MiR-181 family: Regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets

Oncogene

Volumn 34, Issue 25, 2015, Pages 3226-3239

  Su, R ^a   Lin, H S ^a   Zhang, X H ^b   Yin, X L ^b   Ning, H M ^c   Liu, B ^c   Zhai, P F ^a   Gong, J N ^a   Shen, C ^a   Song, L ^a   Chen, J ^a   Wang, F ^a   Zhao, H L ^a   Ma, Y N ^a   Yu, J ^a   Zhang, J W ^a  

^a Department of Pharmacology   (China)

^b The 303rd Hospital of PLA   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD11B ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CTDSPL PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 181; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDES AND PROTEINS; PRKCD PROTEIN; UNCLASSIFIED DRUG; CAMKK1 PROTEIN, HUMAN; CCAAT ENHANCER BINDING PROTEIN; CTDSPL PROTEIN, HUMAN; MIRN181 MICRORNA, HUMAN; PHORBOL 13 ACETATE 12 MYRISTATE; PRKCD PROTEIN, HUMAN; PROTEIN KINASE C DELTA; RETINOIC ACID; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HL 60 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMOGENESIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENOMEGALY; ANIMAL; BOVINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; GRANULOCYTE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PATHOLOGY; RAT; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; BASE SEQUENCE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CATTLE; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MACROPHAGES; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; MYELOID CELLS; PROTEIN KINASE C-DELTA; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRANSDUCTION, GENETIC; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84934974299     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.274     Document Type: Article

References (50)

1. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007; 7: 105-117.
2. Egeland T, Steen R, Quarsten H, Gaudernack G, Yang YC, Thorsby E. Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3. Blood 1991; 78: 3192-3199.
3. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
5. Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999; 5: 669-676.
6. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
7. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
8. Yendamuri S, Calin GA. The role of microRNA in human leukemia: a review. Leukemia 2009; 23: 1257-1263.
9. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768-1778.
10. Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012; 119: 4992-5004.
11. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 2010; 23: 997-1003.
12. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-480.
13. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST et al. TGFbetamediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29: 1787-1797.
14. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009; 50: 1854-1859.
15. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885-12890.
16. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013; 12: 1679-1687.
17. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 2013; 123: 150-163.
18. Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-McIver A, Young BD. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007; 21: 912-916.
19. Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 2009; 28: 4034-4040.
20. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26: 4148-4157.
21. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736-741.
22. Georgantas RW 3rd, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-2755.
23. Kikkawa U, Matsuzaki H, Yamamoto T. Protein kinase C delta (PKC delta): activation mechanisms and functions. J Biochem 2002; 132: 831-839.
24. Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK et al. Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003; 278: 32544-32551.
25. Nitti M, Furfaro AL, Cevasco C, Traverso N, Marinari UM, Pronzato MA et al. PKC delta and NADPH oxidase in retinoic acid-induced neuroblastoma cell differentiation. Cell Signal 2010; 22: 828-835.
26. Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S et al. PRR5L degradation promotes mTORC2-mediated PKC-delta phosphorylation and cell migration downstream of Galpha12. Nat Cell Biol 2012; 14: 686-696.
27. Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood 2004; 104: 3731-3738.
28. Chen C, Du J, Feng W, Song Y, Lu Z, Xu M et al. beta-Adrenergic receptors stimulate interleukin-6 production through Epac-dependent activation of PKCdelta/p38 MAPK signalling in neonatal mouse cardiac fibroblasts. Br J Pharmacol 2012; 166: 676-688.
29. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13.
30. Kashuba VI, Li J, Wang F, Senchenko VN, Protopopov A, Malyukova A et al. RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies. Proc Natl Acad Sci USA 2004; 101: 4906-4911.
31. Dick FA, Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 2003; 12: 639-649.
32. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129: 147-161.
33. Fragoso R, Mao T, Wang S, Schaffert S, Gong X, Yue S et al. Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1. PLoS Genet 2012; 8: e1002855.
34. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012; 119: 2314-2324.
35. Cuesta R, Martinez-Sanchez A, Gebauer F. miR-181a regulates cap-dependent translation of p27(kip1) mRNA in myeloid cells. Mol Cell Biol 2009; 29: 2841-2851.
36. Ke G, Liang L, Yang JM, Huang X, Han D, Huang S et al. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene 2013; 32: 3019-3027.
37. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005; 106: 1362-1368.
38. Feng W, Song Y, Chen C, Lu ZZ, Zhang Y. Stimulation of adenosine A(2B) receptors induces interleukin-6 secretion in cardiac fibroblasts via the PKC-delta-P38 signalling pathway. Br J Pharmacol 2010; 159: 1598-1607.
39. Rahman A, Anwar KN, Uddin S, Xu N, Ye RD, Platanias LC et al. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. Mol Cell Biol 2001; 21: 5554-5565.
40. Studzinski GP, Wang X, Ji Y, Wang Q, Zhang Y, Kutner A et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005; 97: 47-55.
41. Senchenko VN, Anedchenko EA, Kondratieva TT, Krasnov GS, Dmitriev AA, Zabarovska VI et al. Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 2010; 10: 75.
42. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW et al. MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 2012; 31: 80-92.
43. Soderling TR. The Ca-calmodulin-dependent protein kinase cascade. Trends Biochem Sci 1999; 24: 232-236.
44. Verploegen S, Ulfman L, van Deutekom HW, van Aalst C, Honing H, Lammers JW et al. Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte function. Blood 2005; 106: 1076-1083.
45. Lawson ND, Zain M, Zibello T, Picciotto MR, Nairn AC, Berliner N. Modulation of a calcium/calmodulin-dependent protein kinase cascade by retinoic acid during neutrophil maturation. Exp Hematol 1999; 27: 1682-1690.
46. Guest CB, Deszo EL, Hartman ME, York JM, Kelley KW, Freund GG. Ca2+/calmodulin-dependent kinase kinase alpha is expressed by monocytic cells and regulates the activation profile. PLoS ONE 2008; 3: e1606.
47. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M et al. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol 2006; 8: 278-284.
48. Ouyang YB, Lu Y, Yue S, Giffard RG. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2012; 12: 213-219.
49. Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 5257-5264.
50. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928.